Symptoms Associated With Carcinoid Tumours With Features Of Carcinoid Syndrome, Vipomas, and Glucagonomas:
By Sc Inj:
Adult: Initially 50 Mcg 1-2 Times A Day, Adjusted According To Response; Increased To 200 Mcg 3 Times A Day, Higher Doses May Be Required Exceptionally; Maintenance Doses Are Variable; In Carcinoid Tumours, Discontinue After 1 Week If No Effect, If Rapid Response Required, Initial Dose May Be Given By IV Injection (with Ecg Monitoring And After Dilution)
Acromegaly, Short-term Treatment Before Pituitary Surgery Or Long-term Treatment In Those Inadequately Controlled By Other Treatment Or Until Radiotherapy Becomes Fully Effective:
By Sc Inj:
Adult: 100-200 Mcg 3 Times A Day, Discontinue If No Improvement Within 3 Months
Prevention Of Complications Following Pancreatic Surgery:
By Sc Inj:
Adult: (consult Product Literature)
Test Dose Before Use Of Depot Preparation:
By Sc Inj:
Adult: Test Dose 50-100 Mcg For 1 Dose, Test Dose Should Be Given If Subcutaneous Octreotide Not Previously Given
Acromegaly, Neuroendocrine (particularly Carcinoid) Tumour Adequately Controlled By Subcutaneous Octreotide:
By Deep IM Inj Using Depot Inj:
Adult: Initially 20 Mg Lar Injection Every 4 Weeks For 3 Months Then Adjusted According To Response, Increased If Necessary Up To 30 Mg Lar Injection Every 4 Weeks, To Be Administered Into The Gluteal Muscle, For Acromegaly, Start Depot 1 Day After The Last Dose Of Subcutaneous Octreotide, For Neuroendocrine Tumours, Continue Subcutaneous Octreotide For 2 Weeks After First Dose Of Depot Octreotide
Advanced Neuroendocrine Tumours Of The Mid Gut, Or Tumours Of Unknown Primary Origin Where Non-mid Gut Sites Of Origin Have Been Excluded:
By Deep IM Inj Using Depot Inj:
Adult: 30 Mg Lar Injection Every 4 Weeks
Reduce Intestinal Secretions In Palliative Care and reduce Vomiting Due To Bowel Obstruction In Palliative Care: By Continuous Sc Infusion:
Adult: 0.25-0.5 Mg/24 Hours (max. Per Dose0.75 Mg/24 Hours), Occasionally Doses Higher Than The Maximum Are Sometimes Required
Content
Inj 0.05mg /0.1mg: Per 1 ml Amp: Octreotide (as Acetate) 0.05mg /0.1mg; Solution.
Inj: Octreotide (as Acetate) 20mg; Micro-spheres For Susp; In Vials Plus 2 Amp Of Diluent, Syringe And 2 N
Pregnancy
Consult with Doctor Or Caution Advised
Stability
Somatostatin Analogue
Contra Indications
Pregnancy, Lactation.
Precautions
Pregnancy, Lactation.
Lactation
Consult with Doctor Or Caution Advised
Side Effects
Alopecia
Arrhythmias
Biliary Colic (associated With Abrupt Withdrawal Of Subcutaneous Octreotide)
Bradycardia
Dehydration
Dizziness
Dyspnea
Headache
Hepatitis
Pancreatitis (associated With Abrupt Withdrawal Of Subcutaneous Octreotide)